Andrew Moreno

Articles by Andrew Moreno

Andrew MorenoMyelodysplastic Syndromes | November 21, 2024
The favorable effects from vamifeport pharmacologic iron restriction were enhanced by combination with luspatercept.
Andrew MorenoMyelodysplastic Syndromes | November 21, 2024
The model's superior engrafting of HSPCs from patients with MDS brings better replication of the disease microenvironment.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
Jamile Shammo, MDMyelodysplastic Syndromes | November 15, 2024
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
Andrew MorenoChronic Myeloid Leukemia | November 13, 2024
Adverse events were common in patients with CML receiving first- or second-generation tyrosine kinase inhibitors.
Andrew MorenoChronic Lymphocytic Leukemia | November 13, 2024
Venetoclax plus ibrutinib was associated with lower rates of mortality and serious adverse events than the control regimens.
Andrew MorenoAcute Myeloid Leukemia | November 13, 2024
MDS-related gene mutations and number of mutations did not correlate with worse outcomes.
Andrew MorenoAcute Lymphoblastic Leukemia | November 13, 2024
The one-year overall survival rate of 90%, and the MRD negativity rate was 94%.
Andrew MorenoT-Cell Lymphoma | November 11, 2024
The study used CRISPR screening to identify susceptibility markers for brentuximab vedotin in CD30-positive PTCLs.
Andrew MorenoT-Cell Lymphoma | November 12, 2024
Consensus clinical practice recommendations regarding use of this potentially curative procedure had previously been absent.
Andrew MorenoT-Cell Lymphoma | November 8, 2024
Recent advances in knowledge about PTCL biology help inform clinical trial design and use of precision therapy.
Andrew MorenoAcute Myeloid Leukemia | November 6, 2024
The phase II component of this clinical trial evaluating ziftomenib for heavily pretreated AML is in progress.
Andrew MorenoPrint | November 5, 2024
A retrospective study highlighted differences in infection rates and healthcare utilization following CAR-T therapy.
Andrew MorenoPrint | November 4, 2024
A phase II trial in patients with at least three prior treatments evaluated two target doses of the CAR T-cell therapy.
Andrew MorenoT-Cell Lymphoma | November 13, 2024
Co-authors of a new review article suggest other factors more strongly influence secondary tumor development.
Andrew MorenoT-Cell Lymphoma | November 13, 2024
A single-center study compared the secondary and initial tumors and assessed vector viral integration's role in oncogenesis.
Andrew MorenoPrint | November 4, 2024
The agent is newly approved in polytherapy with bortezomib and dexamethasone for multiple myeloma in adults.
Andrew MorenoTransplantation & Cellular Therapy | October 24, 2024
A study has compared responses with anti-CD19 CAR-T therapy in MCL with and without active CNS involvement at infusion.
Andrew MorenoTransplantation & Cellular Therapy | October 24, 2024
An MAIC analysis of data from clinical trials identified differences in efficacy and safety between the two interventions.